Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial)

Apurva O. Badheka, Nileshkumar J. Patel, Peeyush M. Grover, Neeraj Shah, Nilay Patel, Vikas Singh, Abhishek J. Deshmukh, Kathan Mehta, Ankit Chothani, Ghanshyambhai T. Savani, Shilpkumar Arora, Ankit Rathod, George R. Marzouka, James Lafferty, Jawahar L. Mehta, Raul Mitrani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.

Original languageEnglish
Pages (from-to)727-736
Number of pages10
JournalAmerican Journal of Cardiology
Volume114
Issue number5
DOIs
StatePublished - Sep 1 2014

Fingerprint

Atrial Fibrillation
Blood Pressure
Mortality
Ventricular Fibrillation
Bradycardia
Ventricular Tachycardia
Pulmonary Embolism
Proportional Hazards Models

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial). / Badheka, Apurva O.; Patel, Nileshkumar J.; Grover, Peeyush M.; Shah, Neeraj; Patel, Nilay; Singh, Vikas; Deshmukh, Abhishek J.; Mehta, Kathan; Chothani, Ankit; Savani, Ghanshyambhai T.; Arora, Shilpkumar; Rathod, Ankit; Marzouka, George R.; Lafferty, James; Mehta, Jawahar L.; Mitrani, Raul.

In: American Journal of Cardiology, Vol. 114, No. 5, 01.09.2014, p. 727-736.

Research output: Contribution to journalArticle

Badheka, AO, Patel, NJ, Grover, PM, Shah, N, Patel, N, Singh, V, Deshmukh, AJ, Mehta, K, Chothani, A, Savani, GT, Arora, S, Rathod, A, Marzouka, GR, Lafferty, J, Mehta, JL & Mitrani, R 2014, 'Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial)', American Journal of Cardiology, vol. 114, no. 5, pp. 727-736. https://doi.org/10.1016/j.amjcard.2014.06.002
Badheka, Apurva O. ; Patel, Nileshkumar J. ; Grover, Peeyush M. ; Shah, Neeraj ; Patel, Nilay ; Singh, Vikas ; Deshmukh, Abhishek J. ; Mehta, Kathan ; Chothani, Ankit ; Savani, Ghanshyambhai T. ; Arora, Shilpkumar ; Rathod, Ankit ; Marzouka, George R. ; Lafferty, James ; Mehta, Jawahar L. ; Mitrani, Raul. / Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial). In: American Journal of Cardiology. 2014 ; Vol. 114, No. 5. pp. 727-736.
@article{0778b318abba4231b2687bba9123c07e,
title = "Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial)",
abstract = "Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a {"}U-shaped{"} curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.",
author = "Badheka, {Apurva O.} and Patel, {Nileshkumar J.} and Grover, {Peeyush M.} and Neeraj Shah and Nilay Patel and Vikas Singh and Deshmukh, {Abhishek J.} and Kathan Mehta and Ankit Chothani and Savani, {Ghanshyambhai T.} and Shilpkumar Arora and Ankit Rathod and Marzouka, {George R.} and James Lafferty and Mehta, {Jawahar L.} and Raul Mitrani",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2014.06.002",
language = "English",
volume = "114",
pages = "727--736",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial)

AU - Badheka, Apurva O.

AU - Patel, Nileshkumar J.

AU - Grover, Peeyush M.

AU - Shah, Neeraj

AU - Patel, Nilay

AU - Singh, Vikas

AU - Deshmukh, Abhishek J.

AU - Mehta, Kathan

AU - Chothani, Ankit

AU - Savani, Ghanshyambhai T.

AU - Arora, Shilpkumar

AU - Rathod, Ankit

AU - Marzouka, George R.

AU - Lafferty, James

AU - Mehta, Jawahar L.

AU - Mitrani, Raul

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.

AB - Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.

UR - http://www.scopus.com/inward/record.url?scp=84908375946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908375946&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.06.002

DO - 10.1016/j.amjcard.2014.06.002

M3 - Article

VL - 114

SP - 727

EP - 736

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -